Dylan Grassie

Dylan Grassie

Auto-generated profile, based on publicly available information

Dylan Grassie

Drug Discovery Department, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL, USA

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
28 October 2021 in Journal of Medicinal Chemistry
Verified
Journal Article
Closed access
RKRezaul Md Karim
Rezaul Md Karim
MBMelissa J. Bikowitz
Melissa J. Bikowitz
ACAlice Chan
Alice Chan
JZJin-Yi Zhu
Jin-Yi Zhu
DGDylan Grassie
Dylan Grassie
ESErnst Schonbrunn
Ernst Schonbrunn

11 October 2024 in RSC Chemical Biology
Verified
Journal Article
Open access
PDF file
PGPompom Ghosh
Pompom Ghosh
MSMaximilian Schmitz
Maximilian Schmitz
TPThiyagamurthy Pandurangan
Thiyagamurthy Pandurangan
SZSolomon Tadesse Zeleke
Solomon Tadesse Zeleke
SCSean Chin Chan
Sean Chin Chan
AMAndrii Monastyrskyi
Andrii Monastyrskyi
De novo design of molecular glues transforming CDK12 inhibitors, including dinaciclib, into cyclin K degraders.

23 July 2026 in Science
Verified
Journal Article
Closed access
ZSZachary P. Shultz
Zachary P. Shultz
ALAnsar Lee-Sam
Ansar Lee-Sam
YCYun-Pu Chang
Yun-Pu Chang
LSLuxin Sun
Luxin Sun
DGDylan Grassie
Dylan Grassie
JLJustin M. Lopchuk
Justin M. Lopchuk
Covalent inhibition continues to gain momentum as a strategy for selective protein modulation in both therapeutic and chemical biology contexts. Covalent reactive groups (CRGs) typically engage nucleophilic residues such as cysteine, resulting in targeted protein inactivation. However, common electrophiles such as acrylamides often suffer from nonselective reactivity, leading to off-target effects and toxicity. To overcome these limitations, we developed a modular sulfur(IV) reagent platform for the mild, late-stage installation of sulfonyl- and sulfonimidoyl-bicyclobutane motifs with complete cysteine selectivity. This methodology enables access to diverse sulfur(VI) CRGs with tunable strain-release reactivity. Incorporation into US Food and Drug Administration–approved covalent inhibitors demonstrated effective bioisosteric replacement of acrylamides and the potential of strain-release CRGs for selective protein targeting. Preclinical studies in mice have validated this approach, highlighting its promise for next-generation covalent drug design.

14 January 2026 in Journal of Medicinal Chemistry
Verified
Journal Article
Closed access
TPThiyagamurthy Pandurangan
Thiyagamurthy Pandurangan
SZSolomon Tadesse Zeleke
Solomon Tadesse Zeleke
AIAnna Iermolaieva
Anna Iermolaieva
PGPompom Ghosh
Pompom Ghosh
JMJohn Mosior
John Mosior
AMAndrii Monastyrskyi
Andrii Monastyrskyi

7 October 2026 in Journal of Medicinal Chemistry
Verified
Journal Article
Closed access
SCSean Chin Chan
Sean Chin Chan
SBSimon Bayle
Simon Bayle
MLMicheal Lamptey
Micheal Lamptey
ALAnsar Lee-Sam
Ansar Lee-Sam
LSLuxin Sun
Luxin Sun
AMAndrii Monastyrskyi
Andrii Monastyrskyi